ketorolac has been researched along with Gastroduodenal Ulcer in 3 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the risk of hospitalization for gastroduodenal ulcer associated with the use of ketorolac and other non-steroidal anti-inflammatory drugs (NSAIDs)." | 5.08 | Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy. ( Da Cas, R; Maggini, M; Menniti-Ippolito, F; Raschetti, R; Traversa, G; Walker, AM, 1998) |
| "Parecoxib sodium is an injectable prodrug of the cyclooxygenase-2-specific inhibitor valdecoxib that has exhibited analgesic activity in previous trials." | 2.70 | Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. ( Goldstein, JL; Harris, SI; Hubbard, RC; Kuss, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Traversa, G | 2 |
| Walker, AM | 2 |
| Ippolito, FM | 1 |
| Caffari, B | 1 |
| Capurso, L | 1 |
| Dezi, A | 1 |
| Koch, M | 1 |
| Maggini, M | 2 |
| Alegiani, SS | 1 |
| Raschetti, R | 2 |
| Menniti-Ippolito, F | 1 |
| Da Cas, R | 1 |
| Harris, SI | 1 |
| Kuss, M | 1 |
| Hubbard, RC | 1 |
| Goldstein, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Comparison Between Parecoxib and Placebo Added to a Standard Perioperative Analgesic Protocol for Total Knee Arthroplasty[NCT05924412] | Phase 4 | 40 participants (Anticipated) | Interventional | 2023-07-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ketorolac and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control S | 1998 |
Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
Topics: Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxyg | 2001 |
1 other study available for ketorolac and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control St | 1995 |